ReNeuron Demonstrates Key Characteristics with its Hepatocyte Cell Lines
News Oct 31, 2005
ReNeuron Group plc has announced that it has developed human hepatocyte cell lines using its proprietary c-mycERTAM platform technology.
These cell lines have been shown to express a range of adult human liver functional markers, indicating their potential value as a tool in assessing drugs in terms of hepatic metabolism, enzyme induction and cellular toxicity.
The study was conducted in collaboration with Professor Peter Goldfarb and colleagues at the Molecular Toxicology Group, School of Biomedical & Molecular Sciences, University of Surrey, Guildford, UK.
The work is being presented at the 13th North American International Society for the Study of Xenobiotics Meeting in Maui, Hawaii, USA, and was funded in part by a grant under the UK Department of Trade and Industry Knowledge Transfer Partnership Scheme.
ReNeuron has filed patents covering the production of hepatocyte cell lines using its c-mycERTAM platform. Further work is underway to optimize the production and characterization of these cell lines, ahead of making them commercially available to the pharmaceutical industry as part of ReNeuron’s existing ReNcell product portfolio of cell lines for use in drug discovery applications.
Commenting on the announcement, John Sinden, CSO of ReNeuron, said, “The development of functional and patent-protected hepatocyte cell lines is a significant step forward in ReNeuron’s strategy of applying its world-class stem cell technologies in both therapeutic and non-therapeutic settings.”
“We believe that this addition to our ReNcell range of non-therapeutic cell lines represents an exciting commercial prospect for ReNeuron. It offers well-characterised human, rather than animal, cells for toxicology profiling and other high-throughput screening applications in the drug development process.”
“This development further supports our strategy to derive near-term commercial revenues from our ReNcell products to contribute to the funding of our core stem cell therapeutic programmes.”